Becton Dickinson & Co.‘s (NYSE:BDX) C.R. Bard (NYSE:BCR) and subsidiary Davol this week avoided a lawsuit over allegedly defective hernia meshes after an appellate panel reaffirmed a lower court’s dismissal. The lower court had dismissed the suit on the grounds that the operating physician in the case was informed of risks associated with the mesh, eliminating […]
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Medical product distributor RAM Medical Inc. admitted this week to importing and reselling counterfeit and contaminated surgical hernia mesh products.
The Wayne, N.J.-based company pled guilty to two counts of introducing adulterated and misbranded med-tech into interstate commerce, including some that contained numerous microorganisms, according to the U.S. Attorney Paul Fishman.
C.R. Bard Inc. (NYSE:BCR) will pay $184 million to settle most of the lawsuits against subsidiary Davol Inc.’s hernia repair products.
Through late last year, more than 2,700 plaintiffs had filed suit in either federal or state courts pursuing product-liability claims for personal injuries, with most of those cases since transferred to the U.S. District Court for Rhode Island.
The FDA issued a Class I recall of a surgical graft manufactured by C.R. Bard Inc. (NYSE:BCR) subsidiary Davol Inc. on fears it might contain a toxin.
The federal watchdog agency is recalling several lots of Davol’s XenMatrix product because of concerns that it might contain elevated levels of endotoxins. The toxins, which are found in certain bacteria, can cause fatal illness at higher levels, according to the FDA.
A North Carolina couple will collect $1.5 million from C.R. Bard Inc. (NYSE:BCR) after a jury ruled in their favor in a product liability lawsuit over one of Bard’s line of hernia-repair products.
With the first of what may be a long string of product-liability trials now only months away, C.R. Bard Inc. (NYSE:BCR) has convinced an insurance carrier to again cover potential claims.
All it took was letting a $25 million IOU slide.